Gliding motility of the size-modified HMW2-derivative mutants. by Daisuke Nakane (833480)

Developmental regulation of BLBP-positive radial glia and BrdU-positive proliferative cells in the <i>Xenopus</i> tectum. by Yi Tao (178829)

“…Quantification of BrdU- and BLBP-positive cells in whole-mount tecta showed decreases in the numbers of BrdU- and BLBP-labeling cells at stage 49 compared to stage 46 (BrdU: St 46, 288.3 ± 24.7, N = 3, St 49, 78.0 ± 7.4, N = 5; BLBP: St 46, 371.3 ± 28.4, N = 3, St 49, 105.2 ± 8.2, N = 5; ***p<0.001). …”

DataSheet_1_Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basili... by Cong Cheng (2140318)

“…Hence, it was helpful to decrease steroid to the 50% of initial dose ≤ 5 days and to the low-dose steroid ≤ 12 days after basiliximab treatment for intestinal SR-aGVHD patients, which may also be the reasonable steroid decrease protocol for these patients.…”

The <i>Tnni2^K175del</i> mutation disturbed bone development of mice. by Xiaoquan Zhu (589276)

“…<p>Skeletons staining using Alcian blue for cartilage (blue) and Alizarin Red S for calcified bone (red). (A) Decreased mineralization (<i>arrows</i>) in the calvarias from <i>Tnni2^{K175del/K175del}</i> mice at E16.5 and from <i>Tnni2^+K175del</i> mice at P2 and P5 compared to their wild-type littermates, respectively. …”

Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments by Stefania Ferro (76724)

“…The crystal structures of TyBm with inhibitor <b>3</b> (IC₅₀ value of 25.11 μM) and <b>16</b> (IC₅₀ value of 5.25 μM) were solved, confirming the binding poses hypothesized by in silico studies and revealing the main molecular determinants for the binding recognition of the inhibitors.…”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…Upon additional modifications of corallorazine D, a candidate compound <b>5k</b>, demonstrated remarkable inhibitory potency against HDAC8 (IC₅₀ = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. …”